2.10
-0.02(-0.94%)
Currency In USD
| Previous Close | 2.12 |
| Open | 2.09 |
| Day High | 2.17 |
| Day Low | 2.07 |
| 52-Week High | 4.08 |
| 52-Week Low | 0.77 |
| Volume | 397,061 |
| Average Volume | 1.41M |
| Market Cap | 290.39M |
| PE | -5.25 |
| EPS | -0.4 |
| Moving Average 50 Days | 1.93 |
| Moving Average 200 Days | 1.98 |
| Change | -0.02 |
If you invested $1000 in Compass Therapeutics, Inc. (CMPX) since IPO date, it would be worth $247.06 as of June 01, 2025 at a share price of $2.1. Whereas If you bought $1000 worth of Compass Therapeutics, Inc. (CMPX) shares 3 years ago, it would be worth $719.18 as of June 01, 2025 at a share price of $2.1.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 28, 2025 12:00 PM GMT
BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate i
Compass Therapeutics to Participate in Upcoming May Investor Events
GlobeNewswire Inc.
May 06, 2025 12:00 PM GMT
BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate i
Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire Inc.
Apr 28, 2025 12:00 PM GMT
CTX-471 monotherapy demonstrated efficacy in multiple murine models, including models highly resistant to immune checkpoint inhibitors.Combining CTX-471 with tovecimig (CTX-009) markedly increased anti-tumor efficacy in these models.Tovecimig in comb